EGFR and non-small cell lung carcinoma: In the Phase III FLAURA study (NCT02296125), osimertinib provided superior progression-free survival (PFS) versus comparator EGFR-TKIs (erlotinib or gefitinib) in patients with previously untreated EGFRm advanced NSCLC (median 18.9 months versus 10.2 months; hazard ratio [HR] 0.46, 95% confidence interval [CI], 0.37 to 0.57; P < 0.001)11.